

## ASX Announcement

### Investor webinar – CAR T naïve lymphomas & ASH presentation

---

**Sydney, Australia, 4 November 2025:** Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce that it will hold a webinar presentation to update shareholders, investors and other interested parties, discussing the encouraging early efficacy seen in CAR T naïve lymphomas as part of the Company's azer-cel Phase 1b trial (see ASX announcement 29 October 2025), in addition to the oral presentation on azer-cel at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

The webinar will be hosted by CEO & Managing Director Leslie Chong and Chief Medical Officer Dr John Byon.

The webinar will be held at 10am AEDT on Wednesday 5 November 2025.

Shareholders, investors and interested parties can register to attend the webinar at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_e2i4cf4zR3Cdr95C6\\_PBoA](https://us02web.zoom.us/webinar/register/WN_e2i4cf4zR3Cdr95C6_PBoA)

Shareholders are encouraged to submit questions for the webinar in advance via email at: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels.

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
[info@imugene.com](mailto:info@imugene.com)

**General Investor Enquiries**  
[shareholderenquiries@imugene.com](mailto:shareholderenquiries@imugene.com)



## Media Enquiries

Matt Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

## About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.*